Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAquis Exchange Regulatory News (AQX)

  • This share is currently suspended. It was suspended at a price of 725.00
  • There is currently no data for AQX

Form 8.5 (EPT/RI)

12 Dec 2024 10:13

RNS Number : 8803P
Panmure Liberum Limited
12 December 2024
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Panmure Liberum Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Aquis Exchange plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Aquis Exchange plc

(d) Date dealing undertaken:

11 Dec 2024

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

10p ordinary

Purchase

4,843

7.0 GBP

7.0 GBP

10p ordinary

Sales

5,343

7.0 GBP

7.0 GBP

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing, or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

 

Date of disclosure:

12/12/2024

Contact name:

Rosie Kinsella

Telephone number:

+44 (0)207 886 2574

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERMZMMZGZFGDZM
Date   Source Headline
4th Apr 20227:00 amRNSDirector/PDMR Dealing
1st Apr 20223:53 pmRNSTransfer of UBS MTF Business Activities Completed
30th Mar 20229:35 amRNSExercise of Share Options and Total Voting Rights
29th Mar 20227:10 amRNSFinal Results and Board Appointments
29th Mar 20227:00 amRNSAdmission to Trading on the AQSE Growth Market
16th Mar 20227:00 amRNSTransfer of UBS MTF business activities to Aquis
11th Mar 20227:00 amRNSIntention to Dual List on the AQSE
24th Feb 20227:00 amRNSNotice of Results
8th Feb 20227:00 amRNSAquis Technologies partners with Investre
26th Nov 20219:48 amRNSExercise of Share Options and Total Voting Rights
26th Nov 20217:00 amRNSAppointment of New Chair
25th Nov 20217:00 amRNSDirector/PDMR Notification
23rd Sep 20215:39 pmRNSExercise of Share Options, Director Dealing & TVR
23rd Sep 20217:00 amRNSInterim Results
17th Sep 20217:00 amRNSBoard Appointment
1st Sep 20217:00 amRNSNotice of Results
25th Aug 20217:00 amRNSAppointment of independent NED to AQSE Board
2nd Aug 20217:00 amRNSAquis Exchange achieves record market share
28th Jun 20214:21 pmRNSExercise of Share Options and Director Dealing
27th May 20217:00 amRNSAQSE expands research for its top-tier stocks
18th May 20217:00 amRNSDual quotations with the Frankfurt Stock Exchange
13th May 20217:00 amRNSNew Senior Management Appointments
30th Apr 20217:00 amRNSDirector/PDMR Notification & Issue of Options
27th Apr 202112:41 pmRNSResult of Annual General Meeting
8th Apr 20217:00 amRNSDirector/PDMR Notification
31st Mar 20214:51 pmRNSPublication of ARA and Notice of AGM
31st Mar 20217:00 amRNSFinal Results
26th Mar 20217:00 amRNSNotice of Results
24th Mar 20217:00 amRNSAquis Exchange and ShareSoc Retail Investor Survey
26th Feb 20217:00 amRNSTrading and Operational Update
5th Feb 202112:07 pmRNSAppointment of Joint Broker
4th Feb 20218:03 amRNSAquis Exchange recommences trading in Swiss shares
14th Dec 20207:00 amRNSAQSE rule changes & market segments now in effect
26th Nov 20207:00 amRNSDirector/PDMR Notification
23rd Nov 20207:00 amRNSAQSE launches Market Maker Incentive Scheme
20th Nov 20202:00 pmRNSAquis works with SGX & AWS on cloud deployment
19th Oct 20207:00 amRNSAppointment to the AQSE Board
12th Oct 20207:00 amRNSAppointment of Independent Non-executive Director
9th Sep 20207:00 amRNSInterim Results
27th Aug 20207:00 amRNSNotice of Results
17th Jun 20207:00 amRNSBoard Appointment
16th Jun 20207:00 amRNSHolding(s) in Company
15th Jun 20207:01 amRNSDirector/PDMR Notification
15th Jun 20207:00 amRNSIssue of Options and Director/PDMR Notification
19th May 20201:26 pmRNSResult of Annual General Meeting
24th Apr 20207:00 amRNSPublication of ARA and Notice of AGM
20th Apr 20207:00 amRNSIssue of Options and Director/PDMR Notification
16th Apr 20207:00 amRNSFinal results
15th Apr 20207:00 amRNSExercise of Share Options & Total Voting Rights
24th Mar 20207:00 amRNSUpdate to Results Announcement Date

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.